Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Elinzanetant in Renal Impairment
NCT05071729Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elinzanetant in vasomotor symptoms (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve in plasma from zero to infinity (unbound) and Maximum observed (unbound) drug concentration. Started Oct 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05071729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071729.